The first oral GnRH antagonist combined with add-back therapy in Europe, licensed specifically for uterine fibroids1
Balances efficacy and safety1–3
Significantly reduces heavy menstrual bleeding2,3 >85% of women respond to Ryeqo2
Significantly reduces pain associated with uterine fibroids2,3
Significant improvement in quality of life4
Inhibits ovulation and provides adequate contraception after one month of treatment*1
Established safety profile1–3
Bone health preserved during 104 weeks’ treatment1
